Quetiapine for acute bipolar depression: a systematic review and meta-analysis

References

• Merikangas KR Akiskal HS Angst J Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication Arch Gen Psychiatry 2007 64 5 543 552 17485606
   PubMed Web of Science ®Google Scholar
• Woods SW The economic burden of bipolar disease J Clin Psychiatry 2000 61 Supp 13 S38 S41
   PubMed Web of Science ®Google Scholar
• Angst F Stassen HH Clayton PJ Angst J Mortality of patients with mood disorders: follow-up over 34–38 years J Affect Disord 2002 68 2–3 167 181 12063145
   PubMed Web of Science ®Google Scholar
• Goodwin FK Jamison KR Manic-Depressive Illness Oxford Oxford University Press 1990
   Google Scholar
• Suttajit S Srisurapanont M Xia J Suttajit S Maneeton B Maneeton N Quetiapine versus typical antipsychotic medications for schizophrenia Cochrane Database Syst Rev 2013 5 CD007815 23728667
   PubMed Web of Science ®Google Scholar
• Grunze H Vieta E Goodwin GM WFSBP Task Force On Treatment Guidelines For Bipolar Disorders The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression World J Biol Psychiatry 2010 11 2 81 109 20148751
   PubMed Web of Science ®Google Scholar
• Yatham LN Kennedy SH Parikh SV Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013 Bipolar Disord 2013 15 1 1 44 23237061
   PubMed Web of Science ®Google Scholar
• Jensen NH Rodriguiz RM Caron MG Wetsel WC Rothman RB Roth BL N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity Neuropsychopharmacology 2008 33 10 2303 2312 18059438
   PubMed Web of Science ®Google Scholar
• Yatham LN Goldstein JM Vieta E Atypical antipsychotics in bipolar depression: potential mechanisms of action J Clin Psychiatry 2005 66 Suppl 5 40 48 16038601
   PubMed Web of Science ®Google Scholar
• Montgomery SA Asberg M A new depression scale designed to be sensitive to change Br J Psychiatry 1979 134 4 382 389 444788
   PubMed Web of Science ®Google Scholar
• Mayes TL Bernstein IH Haley CL Kennard BD Emslie GJ Psychometric properties of the Children’s Depression Rating Scale-Revised in adolescents J Child Adolesc Psychopharmacol 2010 20 6 513 516 21186970
   PubMed Web of Science ®Google Scholar
• Guy W ECDEU Assessment Manual for Psychopharmacology Rockville, MD US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration 1976
   Google Scholar
• Spearing MK Post RM Leverich GS Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP Psychiatry Res 1997 73 3 159 171 9481807
   PubMed Web of Science ®Google Scholar
• Hamilton M The assessment of anxiety states by rating Br J Med Psychol 1959 32 50 55 13638508
   PubMed Web of Science ®Google Scholar
• Endicott J Nee J Harrison W Blumenthal R Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure Psychopharmacol Bull 1993 29 2 321 326 8290681
   PubMed Web of Science ®Google Scholar
• Buysse DJ Reynolds CF3rd Monk TH Berman SR Kupfer DJ The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res May 1989 28 2 193 213
   Google Scholar
• Sheehan DV The Anxiety Disease New York Scribner’s 1983
   Google Scholar
• Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 3 2011 Oxford The Cochrane Collaboration 2011
   Google Scholar
• Boissel JP Cucherat M Li W The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use Thérapie 1999 54 4 405 411 French 10667106
   PubMed Web of Science ®Google Scholar
• Deeks JJ Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes Stat Med 2002 21 11 1575 1600 12111921
   PubMed Web of Science ®Google Scholar
• Higgins JP Thompson SG Deeks JJ Altman DG Measuring inconsistency in meta-analyses BMJ 2003 327 7414 557 560 12958120
   PubMed Web of Science ®Google Scholar
• AstraZeneca [Webpage on Internet] Effectiveness of Quetiapine XR versus Sertraline in acute depression as add-on therapy to previous mood stabilizer treatment: a pilot study 2012 Available from: http://www.astrazenecaclinicaltrials.com/Submission/View?id=1406 Accessed September 17, 2013
   Google Scholar
• AstraZeneca [Webpage on Internet] A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR) Tablets as Mono-Therapy or in Combination with Lithium in the Treatment of Patients with Acute Bipolar Depression 2012 Available from: http://astrazenecagrouptrials.pharmacm.com/Submission/View?id=1405 Accessed September 17, 2013
   Google Scholar
• Calabrese JR Keck PEJr Macfadden W A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am J Psychiatry 7 2005 162 7 1351 1360 15994719
   PubMed Web of Science ®Google Scholar
• McElroy SL Weisler RH Chang W EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II) J Clin Psychiatry 2010 71 2 163 174 20122366
   PubMed Web of Science ®Google Scholar
• Riesenberg RA Baldytcheva I Datto C Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study Clin Ther 2012 34 11 2202 2211 23059166
   PubMed Web of Science ®Google Scholar
• Suppes T Datto C Minkwitz M Nordenhem A Walker C Darko D Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression J Affect Disord 2010 121 1–2 106 115 19903574
   PubMed Web of Science ®Google Scholar
• Swartz HA Frank E Cheng Y A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression Bipolar Disord 2012 14 2 211 216 22420597
   PubMed Web of Science ®Google Scholar
• Thase ME Macfadden W Weisler RH BOLDER II Study Group Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study) J Clin Psychopharmacol 2006 26 6 600 609 17110817
   PubMed Web of Science ®Google Scholar
• Young AH McElroy SL Bauer M EMBOLDEN I (Trial 001) Investigators A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) J Clin Psychiatry 2010 71 2 150 162 20122369
   PubMed Web of Science ®Google Scholar
• AstraZeneca [Webpage on Internet] An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects with Bipolar Depression 2011 Available from: http://www.astrazenecaclinicaltrials.com/Submission/View?id=1464 Accessed September 17, 2013
   Google Scholar
• DelBello MP Chang K Welge JA A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder Bipolar Disord 2009 11 5 483 493 19624387
   PubMed Web of Science ®Google Scholar
• Bond A Lader M The use of analogue scales in rating subjective feelings British Journal of Medical Psychology 1974 47 3 211 218
   Web of Science ®Google Scholar
• Seeman P Atypical antipsychotics: mechanism of action Can J Psychiatry 2002 47 1 27 38 11873706
   PubMed Web of Science ®Google Scholar
• Marmura MJ Use of dopamine antagonists in treatment of migraine Curr Treat Options Neurol 2012 14 1 27 35 22012659
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV Jevoux C Moreira PF An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine Pain Med 2010 11 1 48 52 20002594
   PubMed Web of Science ®Google Scholar
• Lexchin J Bero LA Djulbegovic B Clark O Pharmaceutical industry sponsorship and research outcome and quality: systematic review BMJ 2003 326 7400 1167 1170 12775614
   PubMed Web of Science ®Google Scholar